Analyst Initiates Sanofi (SNY) with ‘Outperform’ Rating

Sanofi (NASDAQ:SNY) is simply a healthcare biopharmaceutical institution that engages successful the research, development, manufacture, and selling of therapeutic solutions.

On March 19, Bernstein expert Justin Smith initiated sum of Sanofi (NASDAQ:SNY) with an ‘Outperform’ standing and a terms people of €110. The people indicates an upside of 37% from the existent stock price.

Bernstein sees the caller CEO astatine Sanofi (NASDAQ:SNY) unlocking stock value. The French drugmaker appointed Belén Garijo arsenic its caller main enforcement successful February, replacing Paul Hudson, who had led the institution for the past six years. The 65-year-old Spanish executive, who is acceptable to instrumentality complaint successful precocious April, has headed Germany’s Merck KGaA since 2021.

Sanofi (NASDAQ:SNY) stated connected its website:

“Belén Garijo volition bring an accrued rigor to the implementation of Sanofi’s strategy and accelerate the mentation of the Group’s future. Her precedence volition beryllium to fortify the productivity, governance, and innovation capableness of Research & Development.”

The stock terms of Sanofi (NASDAQ:SNY) has declined by implicit 4.5% since the opening of 2026. However, the banal has a guardant P/E ratio of 9.26 and was precocious included successful our database of the 15 Best Undervalued Stocks Under $50 to Invest successful Now.

While we admit the imaginable of SNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Oil Stocks with Highest Dividends and 14 Best Energy Stocks to Buy According to Wall Street Analysts

Disclosure: None. Follow Insider Monkey connected Google News.